Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Short Interest Up 34.6% in December

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totaling 424,089 shares, a growth of 34.6% from the December 15th total of 315,078 shares. Based on an average trading volume of 125,839 shares, the short-interest ratio is currently 3.4 days. Currently, 1.3% of the company’s shares are sold short. Currently, 1.3% of the company’s shares are sold short. Based on an average trading volume of 125,839 shares, the short-interest ratio is currently 3.4 days.

Oramed Pharmaceuticals Stock Down 0.3%

ORMP stock traded down $0.01 during trading on Monday, hitting $3.68. 319,878 shares of the company’s stock traded hands, compared to its average volume of 253,934. The firm has a market capitalization of $146.46 million, a P/E ratio of 2.92 and a beta of 1.19. Oramed Pharmaceuticals has a 1 year low of $1.82 and a 1 year high of $3.71. The business has a fifty day simple moving average of $2.90 and a two-hundred day simple moving average of $2.48.

Oramed Pharmaceuticals Dividend Announcement

The business also recently declared a dividend, which will be paid on Monday, January 26th. Stockholders of record on Friday, January 16th will be given a $0.25 dividend. The ex-dividend date of this dividend is Friday, January 16th.

Institutional Investors Weigh In On Oramed Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. BML Capital Management LLC grew its holdings in shares of Oramed Pharmaceuticals by 2.7% during the third quarter. BML Capital Management LLC now owns 3,167,231 shares of the biotechnology company’s stock valued at $8,361,000 after buying an additional 83,978 shares during the last quarter. Bank of America Corp DE raised its stake in Oramed Pharmaceuticals by 4.4% in the 3rd quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company’s stock worth $395,000 after acquiring an additional 6,261 shares during the last quarter. Jane Street Group LLC lifted its position in Oramed Pharmaceuticals by 35.3% during the 1st quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company’s stock worth $144,000 after acquiring an additional 17,510 shares during the period. Finally, Wealth Enhancement Advisory Services LLC lifted its position in Oramed Pharmaceuticals by 36.2% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 18,799 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 5,000 shares during the period. Institutional investors own 12.73% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Wall Street Zen raised Oramed Pharmaceuticals to a “hold” rating in a research note on Saturday, November 1st. Weiss Ratings reiterated a “hold (c)” rating on shares of Oramed Pharmaceuticals in a report on Monday, December 29th. One research analyst has rated the stock with a Hold rating, According to MarketBeat, Oramed Pharmaceuticals presently has a consensus rating of “Hold”.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.